北京凯晋科技

Kaijin Biotech is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the development of adeno-associated virus (AAV) gene therapies. The company focuses on addressing unmet medical needs in ophthalmology, neurology, and metabolic diseases through its proprietary AAV technology platform. Its lead program, KJ-01, is an investigational gene therapy for Leber Hereditary Optic Neuropathy (LHON) associated with the ND4 mutation, which has entered clinical trials. Kaijin Biotech is backed by prominent venture capital firms including GL Ventures and IDG Capital. The company aims to leverage its expertise in vector design and manufacturing to deliver transformative treatments for patients with genetic disorders.